A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 60
Summary
- Conditions
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Lymphoma
- Mantle Cell Lymphoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02756247
- Collaborators
- Janssen Scientific Affairs, LLC
- Novartis Pharmaceuticals
- Investigators
- Principal Investigator: Connie Batlevi, MD, PhD Memorial Sloan Kettering Cancer Center
Get Well Soon